200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 189691-06-3
189691-06-3 | L-Lysine, N-acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam
CAS No: 189691-06-3 Catalog No: AG002DWJ MDL No:
Product Description
Catalog Number:
AG002DWJ
Chemical Name:
L-Lysine, N-acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2→7)-lactam
CAS Number:
189691-06-3
IUPAC Name:
(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
InChI:
InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
InChI Key:
FFHBJDQSGDNCIV-MFVUMRCOSA-N
UNII:
6Y24O4F92S
Properties
Complexity:
1950
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
7
Defined Bond Stereocenter Count:
0
Exact Mass:
1024.524g/mol
Formal Charge:
0
Heavy Atom Count:
74
Hydrogen Bond Acceptor Count:
12
Hydrogen Bond Donor Count:
13
Isotope Atom Count:
0
Molecular Weight:
1025.182g/mol
Monoisotopic Mass:
1024.524g/mol
Rotatable Bond Count:
17
Topological Polar Surface Area:
379A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.7
Literature
| Title | Journal |
|---|---|
| Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. | Journal of medicinal chemistry 20120308 |
| Central nervous system agents and erectile dysfunction. | The Urologic clinics of North America 20110501 |
| RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. | The journal of sexual medicine 20080401 |
| Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. | The Journal of urology 20080301 |
| Bremelanotide: an overview of preclinical CNS effects on female sexual function. | The journal of sexual medicine 20071101 |
| Clinical application of CNS-acting agents in FSD. | The journal of sexual medicine 20071101 |
| Centrally acting mechanisms for the treatment of male sexual dysfunction. | The Urologic clinics of North America 20071101 |
| Melanocortins in the treatment of male and female sexual dysfunction. | Current topics in medicinal chemistry 20070101 |
| Pharmaceutical aphrodisia. | Current topics in medicinal chemistry 20070101 |
| An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. | The journal of sexual medicine 20060701 |
| Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. | Urology 20050401 |
| Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. | International journal of impotence research 20040401 |
| PT-141 Palatin. | Current opinion in investigational drugs (London, England : 2000) 20040401 |
| Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. | International journal of impotence research 20040201 |
| Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. | Journal of andrology 20040101 |
| PT-141: a melanocortin agonist for the treatment of sexual dysfunction. | Annals of the New York Academy of Sciences 20030601 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.